STOCK TITAN

iBio has until May 18, 2027 to meet Nasdaq’s $1 bid rule

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

iBio, Inc. received notice from Nasdaq that its common stock did not maintain the $1.00 minimum closing bid price for 30 consecutive business days, from October 8 through November 18, 2026. The notice has no immediate effect on listing or trading; the stock continues to trade on The Nasdaq Capital Market under IBIO.

iBio has until May 18, 2027, the end of a 180-calendar-day compliance period, to regain compliance. The closing bid must be at least $1.00 for 10 consecutive business days during that period, although Nasdaq may require more. If iBio does not meet the requirement, it may qualify for another 180 days if it meets other listing standards and gives written notice of its intent to cure by effecting a reverse stock split, if necessary. iBio says it will monitor the bid price and consider options, including a reverse stock split.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNasdaq bid-price deficiency: 30 consecutive business days below $1.00

Filing Explained

The reverse split iBio says it may use if needed is not a decided action; if implemented, it would reduce the share count and proportionally raise the per-share price, while the split itself would not change the company’s value.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Minimum closing bid price $1.00 per share Nasdaq minimum bid-price requirement
Time below minimum bid price 30 consecutive business days October 8 through November 18, 2026
Initial compliance period 180 calendar days Through May 18, 2027
Minimum consecutive-day cure 10 business days Closing bid at or above $1.00 during the initial compliance period
Potential additional compliance period 180 calendar days Conditional on meeting other Nasdaq listing standards and notifying Nasdaq of intent to cure
Minimum Bid Price Requirement regulatory
"the “Minimum Bid Price Requirement”"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"as required by Nasdaq Listing Rule 5550(a)(2)"
continued listing requirement regulatory
"the continued listing requirement for market value of publicly held shares"
Rules a stock exchange sets that a publicly traded company must follow to keep its shares listed, such as minimum share price, market value, shareholder equity, and timely financial reporting. These rules matter to investors because failing them can lead to removal from the exchange, which can make shares harder to buy or sell and often lowers their value — like a club with membership requirements where losing eligibility restricts access and signals trouble.
reverse stock split technical
"including such actions as effecting a reverse stock split, if necessary"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to IBIO’s Nasdaq listing?

Nasdaq notified iBio of a minimum bid-price deficiency after its common stock did not maintain a $1.00 closing bid price for 30 consecutive business days, from October 8 through November 18, 2026. The notice has no immediate effect on listing or trading.

How can IBIO regain Nasdaq’s minimum bid-price compliance?

The closing bid must be at least $1.00 for 10 consecutive business days during the initial 180-calendar-day compliance period. Nasdaq may require the price to remain at or above that threshold for more than 10 consecutive business days.

Can IBIO get more time to meet Nasdaq’s bid-price rule?

iBio may be eligible for an additional 180 calendar days if it meets the other applicable continued-listing and initial-listing standards, except the minimum bid-price requirement, and gives written notice of its intent to cure during the second period by effecting a reverse stock split, if necessary. Nasdaq may notify the company that its stock will be subject to delisting if it appears unable to cure the deficiency or is otherwise ineligible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001420720false00014207202026-11-192026-11-19

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 19, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​

​

001-35023

26-2797813

(Commission File Number)

(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

IBIO

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

​

On November 19, 2026, iBio, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (October 8, 2026 through November 18, 2026), the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”), as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “IBIO.”

​

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until May 18, 2027 (the “Compliance Period”), to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance may be achieved without further action if the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of 10 consecutive business days at any time during the 180-day Compliance Period, in which case Nasdaq will notify the Company if it determines it is in compliance and the matter will be closed; however Nasdaq may, in its discretion, require the closing bid price to equal or to exceed the $1.00 Minimum Bid Price Requirement for more than 10 consecutive business days.

​

If, however, the Company does not achieve compliance with the Minimum Bid Price Requirement by May 18, 2027, the Company may be eligible for additional time to comply. In order to be eligible for such additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s common stock will be subject to delisting.

​

The Company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the Nasdaq listing requirements, including such actions as effecting a reverse stock split, if necessary, to maintain its Nasdaq listing.

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

Date: November 20, 2026

IBIO, INC.

 

 

​

By: 

/s/ Marc A. Banjak

 

 

Name:

Marc A. Banjak

​

​

Title:

Chief Legal Counsel

​

Filing Exhibits & Attachments

4 documents

Keep reading